Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2005

View Archived Issues

Data on the survival effects of seocalcitol in advanced HCC

Remofovir reported to reduce viral load of patients with chronic hepatitis B

LB-80380 shows promise in the treatment of lamivudine-resistant hepatitis B

Idenix presents new data on drugs for chronic hepatitis

Good analgesic efficacy found with lamotrigine plus sertraline in neuropathic pain

Bioaccelerate Holdings and Symbollon enter agreement for IoGen

Cloretazine studied in phase I trial for pediatric brain tumors

SPI-153 enters phase II trial for BPH

Response submitted to FDA for Glumetza NDA

Priority review for SomatoKine

Orchid BioSciences seeks approval to change name to Orchid Cellmark

YM BioSciences to acquire Delex Therapeutics

Lilly licenses therapeutic proteins from Xencor

SCOLR Pharma adds three drug targets to CDT drug development program

Evotec OAI extends discovery chemistry agreement with Roche

Novel analgesic drugs presented in recent patent literature

Chemokine CCR5 modulators and their use as anti-HIV agents claimed by ViroChem and AstraZeneca

Acusphere amends phase III plans for AI-700

SDF-1 antagonist significantly reduces osteosarcoma metastases in animal model

Intranasal Technology inlicenses Aegis' Intravail drug delivery technology

ZSTK-474: a novel PI3K inhibitor with a promising preclinical profile

New indication approved for Hyzaar

Kos and Barr sign agreements to settle Niaspan patent litigation

Avastin improves progression-free survival in phase III breast cancer study

Albuferon safe and active in phase II trial in hepatitis C patients

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...